The Food and Drug Administration on Tuesday evening approved the worldâ€™s first drug designed to stir a womanâ€™s waning desire for sex, a condition that affects an estimated 1 in 10 U.S. women, Washington Post reported.

The approval of the controversial drug, flibanserin, which the FDA twice rejected before and now will be marketed as Addyi, comes with a series of conditions reflecting the agencyâ€™s concerns about serious side effects. These include a boxed warning that highlights the risks of low blood pressure and fainting in patients who drink alcohol while taking the drug, as well as a requirement that doctors complete a training course before being allowed to prescribe it.

â€œBecause of a potentially serious interaction with alcohol, treatment with Addyi will only be available through certified health care professionals and certified pharmacies,â€ Janet Woodcock, director of the FDAâ€™s Center for Drug Evaluation and Research, said in a statement. â€œPatients and prescribers should fully understand the risks associated with the use of Addyi before considering treatment.â€

http://www.washingtonpost.com/rweb/top/fda-approves-controversial-female-viagra-drug/2015/08/18/68d34eca-45f6-11e5-8e7d-9c033e6745d8_story.html?tid=rw_1_menu_slot0

FDA approves female viagra